We round up the big investment news from the past week
OSSTEC raises £2.5m to launch innovative cementless joint replacement technology
London-based startup OSSTEC, a London-based start-up aiming to change the face of joint replacement implants with a novel 3D printing technology, has raised £2.5M in funding.
Based on 10 years of research at Imperial College London, OSSTEC has developed patented 3D-printing technology to mimic both cartilage articulating surfaces and bone-fixing structures.
Its first product has been developed with a world-leading team of surgeons and applies this technology in less invasive knee implants to stimulate bone growth.
With the technology, OSSTEC hopes to fundamentally change orthopaedics by significantly reducing the risk of implant failure or complications and allowing patients to stay active, pain-free and enjoy an improved quality of life.
Max Munford, PhD, CEO and Founder of OSSTEC, said: “This funding marks a pivotal moment for OSSTEC, enabling us to bring our groundbreaking technology to market with our team of surgeons and engage in strategic collaborations to improve patient outcomes.
“We are at the exciting intersection of innovative technology, delivering value for surgeons and patients and high-growth markets, all combined to help more people stay active and pain-free for longer.”
Kidney Research UK invests in Healthinote patient education platform
Kidney Research UK, the leading charity dedicated to kidney health, has made a significant investment in Cognitant Group Ltd, a provider of digital education and support tools to improve the management of long-term health conditions.
A core focus of this partnership is to tackle health inequalities by ensuring that patients from all backgrounds have access to high-quality, culturally relevant information.
Kidney disease disproportionately affects certain communities, particularly those from Black and South Asian backgrounds, who are at higher risk of developing kidney-related conditions.
By xpanding digital education and offering resources in multiple languages and formats, Kidney Research UK and Cognitant aim to break down barriers to healthcare access, improve early diagnosis, and support better long-term disease management for underserved populations.
Katherine Forbes is Director of Innovation and Enterprise at Kidney Research UK.
Forbes said: “Cognitant’s innovative tools will enable patients to have access to evidence-based resources, tailored to their needs, helping to personalise their care.
“By providing this digital, multi-lingual programme, patients should be better informed and empowered in their self care and management of their condition, improving their quality of life and saving patients’ and clinicians’ time.”
Neuranics raises $8m to advance magnetic sensing tech
Scottish deep-tech semiconductor company Neuranics has raised $8 million in seed funding to accelerate global growth and the commercial adoption of its Tunnelling Magnetoresistance (TMR) magnetic sensing technology.
The funding will drive the company’s next phase—strengthening its team, accelerating innovation across core technologies, and enabling widespread integration of its TMR technology into emerging and high-tech markets, including XR, wearables and digital health.
Neuranics’ ultra-sensitive, low-power, and scalable sensors detect tiny magnetic signals from the human body, enabling precise tracking of muscle activity for gesture recognition and heart signals—all without skin contact.
Compared to traditional methods, Neuranics’ magnetic sensing technology offers improved accuracy, reduced power consumption, and the potential for continuous monitoring.
Noel McKenna, CEO of Neuranics, said: “This investment marks a significant step forward as we continue pioneering new applications for magnetic sensing.
“With the support of our investors, we are expanding our team, advancing our technology, and bringing our solutions closer to widespread adoption.”
SecondWave raises $7m Series A
SecondWave Systems, Inc., a clinical stage medical device company developing a novel ultrasound-based treatment for inflammatory disorders, has closed a $7M Series A financing round.
The financing was led by Treo Ventures and a major healthcare strategic, with participation from Scientific Health Development and the University of Minnesota’s Discovery Capital and SSBCI funds.
Proceeds from the financing will support SecondWave’s next clinical study, leveraging the success of their first-in-human study that demonstrated a significant reduction in rheumatoid arthritis disease activity.
SecondWave CEO, Anuj Bhardwaj, said: “As we work to develop and commercialize the SecondWave MINI as a new class of noninvasive therapy, we are very excited to enter the next phase of development with a strong set of new investor partners.
“Our team at SecondWave is dedicated to improving patient quality of life for millions of Americans who suffer from chronic inflammatory disorders.”
Mudit K. Jain, PhD, General Partner, Treo Ventures, added: “We are enthusiastic to partner with SecondWave’s experienced team to advance a novel and highly differentiated therapy that will positively impact the lives of countless patients while reducing the cost of care.”
